Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Pressemeddelelse

BioStock: Strong Q3 performance for Alligator Bioscience

Alligator Bioscience

Alligator Bioscience has reported a productive quarter, showing significant advancements in its cancer therapeutics pipeline, particularly its lead asset mitazalimab, which received Orphan Designation in Europe. Moreover, the company reached another milestone in its partnership with Orion Corporation and strengthened its financial foundation through a successful warrant exercise. The stage is set for a promising final quarter of the year, with key data slated for release in early 2024. BioStock spoke with CEO Søren Bregenholt to learn more.

Read the interview with Søren Bregenholt at biostock.se:

Strong Q3 performance for Alligator Bioscience - BioStock (https://www.biostock.se/en/2023/11/strong-q3-performance-for-alligator-bioscience/)
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team